Gemcitabine, irinotecan and celecoxib in patients with biliary cancer

Anti-Cancer Drugs

Volumn 20, Issue 4, 2009, Pages 294-300

  Watkins, James F ^b   Mayo, Matthew S ^a   Smith, Holly J ^a,c   Williamson, Stephen K ^b,d  

^a Center for Biostatistics and Advanced Informatics   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d Division of Hematology/Oncology   (United States)

Author keywords

Biliary cancer; Celecoxib; Cholangiocarcinoma; Cyclooxygenase; Gallbladder cancer; Hepatobiliary cancer; Metastatic; Unresectable

Indexed keywords

CELECOXIB; GEMCITABINE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CANCER; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRAZOLES; SULFONAMIDES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 63449085936     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283287ca0     Document Type: Article

References (58)

1. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007; 110:1307-1312.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
3. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998; 228:385-394.
4. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75 (1 Suppl):171-190.
5. Nagorney DM, Donohue JH, Farnell MB, Schleck CD, llstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993; 128: 871-877; discussion 7-9.
6. Falkson G, Maclntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54:965-969.
7. Gebbia V, Majello E, Testa A, Pezzella G, Giuseppe S, Giotta F, et al. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a muKicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer 1996; 78:1300-1307.
8. Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH, et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 1993; 4:607-609.
9. Takada T, Kato H, Matsushro T, Nimura Y, Nagakawa T, Nakayama T. Comparison of 5-fluorouracil, dooiorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51396-400.
10. De Gusmao CBRA, Uurad AM, Scalabrini-Neto AO. Phase II trial of the use of gemcitabine (G) and 5-fluorouracil (5-FU) in the treatment of advanced pancreatic (APC) and biliary tract (ABTC) adenocarcinoma [abstract #1116]. Proc Am Soc Clin Oncol 1998; 16 (Suppl):290a.
11. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19:4089-4091.
12. Mezger J, Sauerbruch T, Ko Y, Wolter H, Funk C. Phase II trial of gemcitabine in biliary tract cancers. Proc Am Soc Clin Oncol 1997; 6:297a.
13. Poplin E, Roberts J, Tombs M, Grant S, Rubin E. Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. Invest New Drugs 1999; 17:57-62.
14. Bahadori HR, Rocha Lima CM, Green MR, Safa AR. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999; 19:5423-5428.
15. Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, et al. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Huntingt) 2002; 16 (Suppl 5):19-24.
16. Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Huntingt) 2001; 15 (Suppl 5):46-51.
17. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 1998; 39:581-591.
18. Hoper MM, Voelkel NF, Bates TO, Allard JD, Horan M, Shepherd D, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997; 17:748-756.
19. Legan M, Luzar B, Maroft VF, Cor A. Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 2006; 12:3425-3429.
20. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci 1999; 889:84-86.
21. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999; 90:1152-1162.
22. Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1998; 58:3028-3031.
23. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20:1939-1944.
24. Schmitz KJ, Lang H, Wohlschlaeger J, Reis H, Sotiropoulos GC, Schmid KW, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch 2007; 450:135-141.
25. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105:1589-1594.
26. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woemer BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
27. Chariyalertsak S, Sinkulchayanonta V, Mayer D, Kopp-Schneider A, Furstenberger G, Marks F, ef al. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2001; 48:80-86.
28. Cheifetz RE, Davis NL, Owen DA. An animal model of benign bile-duct stricture, sclerosing cholangitis and cholangiocarcinorna and the role of epidermal growth factor receptor in ductal proliferation. Can J Surg 1996; 39:193-197.
29. Longo WE, Panesar N, Mazuski JE, Kaminski D. Synthetic pathways of gallbladder mucosal prostanoids: the role of cyclooxygenase-1 and 2. Prostaglandins Leukot Bssent Fatty Acids 1999; 60:77-85.
30. Perrons G, Santini D, Verzi A, Vlncenzi B, Borzomati D, Vecchio F, et al. COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. J Clin Pathol 2006; 59:492-496.
31. Santini D, Vmcenzi B, Tonini G, Scarpa S, Vasaturo F, Malacrino C, et al. Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients. Clin Cancer Res 2005; 11:3784-3789.
32. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1989; 59:987-990.
33. Wu GS, Zou SO, Liu ZR, Tang ZH, Wang JH. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 2003; 9:1302-1306.
34. Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 2005; 1755:135-150.
35. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N EnglJ Med 2006; 355:873-884.
36. Hawk E, Viner JL. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev 2007; 16:185-187.
37. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, ef al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
38. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23:425-428.
39. Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998; 45:2020-2026.
40. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48:783-789.
41. Palmeri S, Leonardi V, Gebbia V, De Bella MT, Ferrau F, Faillu G, et al. Gemcitabine plus vinorelbine in stage NIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial. Lung Cancer 2001; 34:115-123.
42. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Onco/2001; 12:183-186.
43. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005; 104:2753-2758.
44. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 2007; 14:3202-3209.
45. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23:2332-2338.
46. Serrano A, Gerson R. Chemotherapy with gemcitabine in advanced biliary tract carcinoma. Rev Recent Clin Trials 2008; 3:70-78.
47. Sun W, Hewitt MR, Theobald MR, Hershock D, Haller DG. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer 2007; 110:2768-2774.
48. Bhargava P, Jani CR, Savarese DM, O'Donnell JL, Stuart KE, Rocha Lima CM. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (HuntingO 2003; 17 (Suppl 8):23-26.
49. Upton A, Harvey H, Witters L, Kerr S, Legore K, Campbell C. Gemcitabine/ irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park, NY) 2004; 18 (Suppl 14):43-45.
50. Lilenbaum R, Socinski MA, Altorki NK, Hart LL, Keresztes RS, Hariharan S, et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/ irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006; 24:4825-4832.
51. Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004; 39:1028-1037.
52. Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 2004; 3:299-307.
53. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60:1326-1331.
54. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 2004; 64:1369-1376.
55. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
56. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102.
57. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. W Engl J Med 2005; 352:1081-1091.
58. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080.